115 related articles for article (PubMed ID: 16190746)
1. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.
Vendôme J; Letard S; Martin F; Svinarchuk F; Dubreuil P; Auclair C; Le Bret M
J Med Chem; 2005 Oct; 48(20):6194-201. PubMed ID: 16190746
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
Foster R; Griffith R; Ferrao P; Ashman L
J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
[TBL] [Abstract][Full Text] [Related]
3. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
4. Computer simulations reveal a novel nucleotide-type binding orientation for ellipticine-based anticancer c-kit kinase inhibitors.
Thompson D; Miller C; McCarthy FO
Biochemistry; 2008 Sep; 47(39):10333-44. PubMed ID: 18754682
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling.
Torrent M; Rickert K; Pan BS; Sepp-Lorenzino L
J Mol Graph Model; 2004 Oct; 23(2):153-65. PubMed ID: 15363457
[TBL] [Abstract][Full Text] [Related]
7. Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR.
Schumacher JA; Elenitoba-Johnson KS; Lim MS
J Clin Pathol; 2008 Jan; 61(1):109-14. PubMed ID: 17526803
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
Healy EF; Johnson S; Hauser CR; King PJ
FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
[TBL] [Abstract][Full Text] [Related]
9. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
[TBL] [Abstract][Full Text] [Related]
10. KIT mutations in mastocytosis and their potential as therapeutic targets.
Gotlib J
Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
[TBL] [Abstract][Full Text] [Related]
11. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
Guida T; Anaganti S; Provitera L; Gedrich R; Sullivan E; Wilhelm SM; Santoro M; Carlomagno F
Clin Cancer Res; 2007 Jun; 13(11):3363-9. PubMed ID: 17545544
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
14. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
[TBL] [Abstract][Full Text] [Related]
15. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.
Laine E; Chauvot de Beauchêne I; Perahia D; Auclair C; Tchertanov L
PLoS Comput Biol; 2011 Jun; 7(6):e1002068. PubMed ID: 21698178
[TBL] [Abstract][Full Text] [Related]
16. Structure-based de novo design and identification of D816V mutant-selective c-KIT inhibitors.
Park H; Lee S; Lee S; Hong S
Org Biomol Chem; 2014 Jul; 12(26):4644-55. PubMed ID: 24853767
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Dual Inhibitors for Wild Type and D816V Mutant of c-KIT Kinase through Virtual and Biochemical Screening of Natural Products.
Park H; Lee S; Hong S
J Nat Prod; 2016 Feb; 79(2):293-9. PubMed ID: 26807861
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
Laufer SA; Domeyer DM; Scior TR; Albrecht W; Hauser DR
J Med Chem; 2005 Feb; 48(3):710-22. PubMed ID: 15689155
[TBL] [Abstract][Full Text] [Related]
19. KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.
Chaix A; Arcangeli ML; Lopez S; Voisset E; Yang Y; Vita M; Letard S; Audebert S; Finetti P; Birnbaum D; Bertucci F; Aurrand-Lions M; Dubreuil P; De Sepulveda P
Oncogene; 2014 Feb; 33(7):872-81. PubMed ID: 23416972
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature.
Kocabas CN; Yavuz AS; Lipsky PE; Metcalfe DD; Akin C
J Allergy Clin Immunol; 2005 Jun; 115(6):1155-61. PubMed ID: 15940128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
